KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Operations: 2011-2025

Historic Cash from Operations for Arbutus Biopharma (ABUS) over the last 15 years, with Sep 2025 value amounting to -$5.8 million.

  • Arbutus Biopharma's Cash from Operations rose 71.95% to -$5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.3 million, marking a year-over-year increase of 36.97%. This contributed to the annual value of -$64.8 million for FY2024, which is 24.54% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Cash from Operations of -$5.8 million as of Q3 2025, which was up 63.06% from -$15.7 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Cash from Operations ranged from a high of $20.6 million in Q1 2022 and a low of -$27.3 million during Q1 2023.
  • Moreover, its 3-year median value for Cash from Operations was -$17.3 million (2023), whereas its average is -$16.9 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first spiked by 215.31% in 2022, then slumped by 232.41% in 2023.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Cash from Operations stood at -$19.6 million in 2021, then climbed by 13.34% to -$17.0 million in 2022, then decreased by 1.78% to -$17.3 million in 2023, then spiked by 40.35% to -$10.3 million in 2024, then skyrocketed by 71.95% to -$5.8 million in 2025.
  • Its Cash from Operations was -$5.8 million in Q3 2025, compared to -$15.7 million in Q2 2025 and -$13.4 million in Q1 2025.